The shutdown of Ameridose LLC was announced in Boston on Wednesday by Dr. Madeleine Biondolillo, deputy director for health safety in Massachusetts.

She said Ameridose, which has the same owners as New England Compounding Center, the company believed to be the source of the fungus tainted steroid, had agreed to a voluntary temporary shutdown to allow state and federal officials to inspect the 70,000-square-foot facility in Westborough, Mass.

Ameridose has a contract to supply member hospitals for Brentwood-based HealthTrust Purchasing Group. The company also announced in early 2010 that it had signed an exclusive supply contract with HCA, the Nashville-based hospital chain that also is part owner of HealthTrust.

Biondolillo said the exact terms of the temporary shutdown agreement were still being worked out. A third company, Alaunus Pharmaceuticals, which acts as a distributor for Ameridose, also will temporarily cease operations, she said.

“There is no recall at this time,” she said, adding that the state had no reason to believe the company was out of compliance with state law.

Biondolillo also announced that the agency was requiring all drug compounding companies operating in the state to file affidavits stating whether they were in compliance with state and federal law.

In a warning to compounding companies, she stressed that they must have an individual prescription for every dose issued. Asked if New England Compounding had violated that requirement, she said the investigation was still in progress.

“Ameridose is voluntarily surrendering its license,” said company spokesman Andrew Paven. “It is a ‘time-delineated agreement.’ They will not recommend providers not use Ameridose products at this time.”

The company later said the agreement called for the closure to last for 12 days. They also disclosed that under the agreement, Barry J. Cadden — a director and part owner of both Ameridose and New England Compounding Center — will step down from all of his corporate positions at Ameridose.

The announcement came on the heels of the disclosure that a longtime member of the state Pharmacy Board, which licenses both firms, has business ties with the owners of Ameridose and New England Compounding Center.

Sophia Pasedis, who has served on the Massachusetts Board of Pharmacy since 2004, is a vice president of Ameridose.

Officials of the Massachusetts Health Department said in a statement that Pasedis had recused herself from any matters before the pharmacy board relating to the two companies.

Pasedis did not respond to messages left for her at Ameridose or at her home in Quincy, Mass.

Because her state position is unpaid, Pasedis is not required to file a financial disclosure report with the state Ethics Commission. She did, however, file a disclosure on May 13, 2008, stating that she believed she could be objective in participating in a pending case involving a licensee with ties to two other board members.

Paven issued a statement stressing that despite their common ownership, the two companies have “separate production facilities, separate processes and operate at separate locations in different cities.”

The two facilities are about eight miles apart in the western suburbs of Boston.